PFCS
RARE icon

Pale Fire Capital SE’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pale Fire Capital SE’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$346K Buy
16,514
+6,303
+62% +$142K 0.03% 43
2025
Q4 		$235K Buy
+10,211
New +$336K 0.02% 45
2025
Q3 		– Sell
-5,600
Closed -$204K – 67
2025
Q2 		$204K Buy
+5,600
New +$202K 0.02% 48

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pale Fire Capital SE's RARE Position: Q1 2026 in Review

Pale Fire Capital SE increased its Ultragenyx Pharmaceutical (RARE) stake by 62% in Q1 2026, buying an estimated $142K and bringing the position to 16,514 shares worth $346K. The position accounts for 0.03% of the portfolio, ranked #43.

Pale Fire Capital SE first reported a position in RARE in Q2 2025 and has held it in 3 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Pale Fire Capital SE held 16,514 shares of Ultragenyx Pharmaceutical worth $346K as of Q1 2026.
  • Pale Fire Capital SE bought 6,303 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $142K.
  • Ultragenyx Pharmaceutical made up 0.03% of Pale Fire Capital SE's portfolio in Q1 2026, its #43 holding.
  • Pale Fire Capital SE first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 3 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Pale Fire Capital SE's 13F filing for Q1 2026, filed 14 May 2026.